Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Daiichi Sankyo has introduced of Cravit intravenous injections (hereafter, Cravit IV), a new formulation of its fluoloquinolone intravenous anti-bacterial agent, Cravit (generi name, levofloxacin hydrate) in Japan.
Subscribe to our email newsletter
Cravit IV, administered once daily, is classified as a respiratory quinolone suited to treat respiratory tract infections.
Daiichi said that 100mg Cravit tablets were approved in Japan for sale in December 1993 and in July 2009.
In Japan, orally administered 100mg Cravit tablets were approved for sale in December 1993 and in July 2009, the once-daily administration with 500mg Cravit was approved in line with the world standard dosage regimen.
Now, Daiichi Sankyo has further expanded treatment options with the addition of Cravit IV.